ACP
KURA icon

Acuta Capital Partners’s Kura Oncology KURA Stock Holding History

Acuta Capital Partners’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-197,000
Closed -$3.85M – 45
2024
Q3 		$3.85M Buy
197,000
+34,000
+21% +$689K 3.12% 12
2024
Q2 		$3.36M Buy
163,000
+73,000
+81% +$1.5M 2.83% 14
2024
Q1 		$1.92M Sell
90,000
-611,349
-87% -$11.9M 1.25% 23
2023
Q4 		$10.1M Sell
701,349
-744
-0.1% -$7.32K 5.68% 4
2023
Q3 		$6.4M Sell
702,093
-7,025
-1% -$71.3K 4.29% 10
2023
Q2 		$7.5M Buy
709,118
+143,861
+25% +$1.7M 5.08% 4
2023
Q1 		$6.91M Buy
565,257
+63,757
+13% +$796K 5.09% 7
2022
Q4 		$6.22M Sell
501,500
-35,000
-7% -$509K 3.83% 12
2022
Q3 		$7.33M Hold
536,500
– – 3.16% 12
2022
Q2 		$9.83M Buy
536,500
+62,531
+13% +$899K 5.48% 4
2022
Q1 		$7.62M Buy
473,969
+182,085
+62% +$2.63M 3.56% 9
2021
Q4 		$4.09M Hold
291,884
– – 1.72% 19
2021
Q3 		$5.47M Sell
291,884
-61,514
-17% -$1.16M 1.93% 17
2021
Q2 		$7.37M Sell
353,398
-183,422
-34% -$4.55M 2.94% 11
2021
Q1 		$15.2M Sell
536,820
-100,680
-16% -$3.19M 5.47% 3
2020
Q4 		$20.8M Sell
637,500
-335,500
-34% -$11.8M 5.67% 3
2020
Q3 		$29.8M Buy
973,000
+100,500
+12% +$2.22M 8.1% 2
2020
Q2 		$14.2M Buy
872,500
+674,500
+341% +$9.73M 4.11% 6
2020
Q1 		$1.97M Sell
198,000
-42,000
-18% -$481K 0.95% 28
2019
Q4 		$3.3M Buy
240,000
+145,000
+153% +$2.15M 0.82% 27
2019
Q3 		$1.44M Buy
+95,000
New +$1.69M 1.04% 20

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acuta Capital Partners's KURA Position: Q4 2024 in Review

Acuta Capital Partners sold out of Kura Oncology (KURA) in Q4 2024, closing a stake of 197,000 shares — an estimated $3.85M sold.

Acuta Capital Partners first reported a position in KURA in Q3 2019 and held it in 21 quarters. The position peaked at $29.8M in Q3 2020. 185 funds tracked by Wall St. Rank hold KURA as of Q4 2024.

  • Acuta Capital Partners reported no remaining Kura Oncology position as of Q4 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 197,000 Kura Oncology shares in Q4 2024, an estimated $3.85M.
  • Acuta Capital Partners first reported a position in Kura Oncology in Q3 2019 and held it in 21 quarters.
  • Acuta Capital Partners's Kura Oncology position peaked at $29.8M in Q3 2020.
  • 185 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2024.

Based on Acuta Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.